After Salix's $10B deal, is Synergy Pharma on the block?

Gastro drug developer Synergy Pharmaceuticals ($SGYP) is considering putting itself up for sale, Bloomberg reports, perhaps emboldened by the high price secured by competitor Salix Pharmaceuticals ($SLXP). Citing people close to the company, Bloomberg says Synergy is talking to its advisers about strategic alternatives, which could include a sale. The report sent Synergy's shares up about 8% on Thursday, as investors hope Salix's $10 billion valuation could portend another big deal in the space. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.